Posted by Michael Wonder on 09 Mar 2020
PhRMA: federal biosimilar payment policies are having a positive effect
4 March 2020 - Katie Verb, director of policy and research for the biopharmaceutical industry group PhRMA, discusses recent policy changes that have increased biosimilar uptake and additional measures that could lead to greater use of biosimilars and savings for CMS and patients.
A perspective from the biopharmaceutical industry on achievements in bringing biosimilars to market and what more can be done to incentivise biosimilar uptake was provided by Katie Verb, director of policy and research for PhRMA at the World Biosimilar Congress 2020 at the Festival of Biologics USA in San Diego, California.
PhRMA, which represents biopharmaceutical manufacturers, believes that amid a spectrum of opinion on the health of the biosimilars market, biosimilars are helping to bring down the cost of drugs in the US market and stand poised to achieve further savings via programs such as the Oncology Care Model and its scheduled replacement, the Oncology Care First model, both of which can drive the use of biosimilars, Verb said. The OCF is slated to start early next year.
